- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02804711
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
A Phase Ia Single-center, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China
Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine.
This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an experimental recombinant staphylococcus aureus vaccine. The study will be carried out following a dose-escalation method from the low dosage to the high dosage, i.e. the higher dosage vaccine could only be administrated after the first seven-day safety of the lower dosage vaccine is confirmed after safety observation.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Jiangsu
-
Taixing, Jiangsu, China, 210009
- Xiaokui Hu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years).
- Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
- Able to understand the content of informed consent and willing to sign the informed consent.
- Able to complete the diary card independently.
- For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
- Axillary temperature ≤37.0°C.
Exclusion Criteria:
First Immunization exclusion standard:
- Prior receipt of Staphylococcus aureus vaccine
- Any confirmed Staphylococcus aureus infection disease in the past 12 month.
- History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
- Prior blood donation or Blood loss over 400ml in the last 3 months;
- Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
- History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain.
- Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease.
- Taking immunoglobulins and/or any blood products within the last 12 months.
- Asplenia, functional asplenia or asplenia caused by any situation or splenectomy.
- Any acute disease or acute attack of chronic disease in last 7 days.
- History of thyroidectomy or thyroid disease requiring treatment in the last 12 months.
- Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment)
- Participation in another research study involving receipt of an investigational product in the last 30 days.
- Woman who is breast-feeding.
- Prior administration of attenuated vaccine in last 28 days.
- Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
- Current anti-tuberculosis prophylaxis or therapy
- Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.
Following Immunization exclusion standard:
- Any grade 3 or more serious adverse reaction happen since the last vaccination.
- Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization.
- Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).
- According to the investigator, the participant should not continue participating in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Four doses of low dose vaccine
four doses of 15µg/0.6ml
per dose
|
|
Experimental: Four doses of middle dose vaccine
four doses of 30µg/0.6ml
per dose
|
|
Experimental: Four doses of high dose vaccine
four doses of 60µg/0.6ml
per dose
|
|
Experimental: Three doses of low dose vaccine and one dose of placebo
three doses of 15µg/0.6ml
per dose and one dose of placebo
|
|
Experimental: Three doses of middle dose vaccine and one dose of placebo
three doses of 30µg/0.6ml
per dose and one dose of placebo
|
|
Experimental: Three doses of high dose vaccine and one dose of placebo
three doses of 60µg/0.6ml
per dose and one dose of placebo
|
|
Placebo-Komparator: Four doses of placebo
four doses of placebo
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Occurrence of injection site adverse reactions after vaccination
Zeitfenster: within 21 days after the vaccination
|
Occurrence of solicited injection site adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine
|
within 21 days after the vaccination
|
Occurrence of systematic adverse reactions after vaccination
Zeitfenster: within 21 days after the vaccination
|
Occurrence of solicited systematic adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine
|
within 21 days after the vaccination
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Auftreten schwerwiegender unerwünschter Ereignisse nach der Impfung.
Zeitfenster: innerhalb von 6 Monaten nach der Impfung
|
Auftreten schwerwiegender unerwünschter Ereignisse innerhalb von 6 Monaten nach der Impfung mit dem rekombinanten Staphylococcus-aureus-Impfstoff
|
innerhalb von 6 Monaten nach der Impfung
|
Occurrence of unsolicited adverse reactions after vaccination.
Zeitfenster: within 42 days after the vaccination
|
Occurrence of unsolicited adverse reactions within 42 days after vaccination with the Recombinant Staphylococcus aureus vaccine
|
within 42 days after the vaccination
|
Changes of the blood routine after vaccination.
Zeitfenster: day 0-17 after the vaccination
|
Changes of the blood routine after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17.
|
day 0-17 after the vaccination
|
Changes of the blood biochemistry after vaccination.
Zeitfenster: day 0-17 after the vaccination
|
Changes of the blood biochemistry after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17.
|
day 0-17 after the vaccination
|
Geometric mean titre against specific antigens
Zeitfenster: within 6 months after the vaccination
|
Geometric mean titre measured at day 0, 7, 14, 21, 42 and month 3, 6.
|
within 6 months after the vaccination
|
Geometric mean fold increase against specific antigens
Zeitfenster: within 6 months after the vaccination
|
Geometric mean fold increase measured at day 7, 14, 21, 42 and month 3, 6.
|
within 6 months after the vaccination
|
Positive conversion rate of serum against specific antigens
Zeitfenster: within 6 months after the vaccination
|
Positive conversion rate of serum measured at day 7, 14, 21, 42 and month 3, 6.
|
within 6 months after the vaccination
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination.
Zeitfenster: within 6 months after the vaccination
|
Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination with the Staphylococcus aureus vaccine at day at day 3, 7, 10, 14, 17, 21, 42 and month 3, 6.
|
within 6 months after the vaccination
|
Specific functional antibody responses to the Staphylococcus aureus vaccine
Zeitfenster: within 6 months after the vaccination
|
Specific functional antibody responses to the Staphylococcus aureus vaccine at day 7, 14, 21, 42 and month 3, 6.
|
within 6 months after the vaccination
|
Specific T cell immune responses to the Staphylococcus aureus vaccine.
Zeitfenster: within 6 months after the vaccination
|
Specific T cell immune responses to the Staphylococcus aureus vaccine at day at day7, 14, 21, 42 and month 3, 6 measured by ELISpot.
|
within 6 months after the vaccination
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Infektionen
- Gramnegative bakterielle Infektionen
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Grampositive bakterielle Infektionen
- Enterobacteriaceae-Infektionen
- Staphylokokken-Infektionen
- Escherichia coli-Infektionen
- Physiologische Wirkungen von Arzneimitteln
- Immunologische Faktoren
- Impfungen
Andere Studien-ID-Nummern
- JSVCT027
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Staphylococcus Aureus-Infektion
-
University Hospital TuebingenNoch keine Rekrutierung
-
Centre Hospitalier Universitaire de Saint EtienneAbgeschlossen
-
University of SheffieldRajarata University, Sri LankaUnbekannt
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...AbgeschlossenStaphylococcus AureusVereinigte Staaten
-
Todd C. Lee MD MPH FIDSANoch keine RekrutierungStaphylococcus Aureus Bakteriämie | Staphylococcus Aureus-Endokarditis | Staphylococcus Aureus Septikämie | Staphylokokken-SepsisKanada
-
Ohio State UniversityAbgeschlossenMethicillin-resistenter Staphylococcus Aureus | Methicillin-empfindliche Staphylococcus Aureus-InfektionVereinigte Staaten
-
Forest LaboratoriesAbgeschlossenStaphylococcus Aureus Bakteriämie | Methicillin-resistente Staphylococcus Aureus (MRSA)-BakteriämieVereinigte Staaten
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRekrutierungBakteriämie | Staphylococcus Aureus | Staphylococcus Aureus Bakteriämie | Bakteriämie durch Staphylococcus Aureus | Bakteriämie StaphVereinigte Staaten, Australien
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... und andere MitarbeiterBeendetMethicillin-resistenter Staphylococcus AureusAustralien, Neuseeland, Israel, Singapur
-
Hospices Civils de LyonAbgeschlossen
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich